Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Wants A Breakthrough Therapy, Even Without All The Standards

Executive Summary

A few requests have gone to FDA for candidates to be named breakthrough therapies and gain access to shorter development programs, but the agency has not established all the program requirements yet.


Related Content

US FDA's Biologics Center Director Expects It Soon Will See 'Growth Spurt'
Breakthrough Designation Can Be 'Lever' For Manufacturing Evolution, FDA Says
Primer On FDA’s "Breakthrough Therapy" Program
FDA To Provide Expedited Approval Desktop Reference
Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
Antibiotic Legislation Offers Big GAIN For Small Firm: Rib-X Extends Delafloxacin Exclusivity
Biosimilar User Fee Meeting Schedule Allows FDA Data “Pre-Review”
With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation
FDA “Breakthrough” Designation Bill Revives Debate About Legislating Flexibility


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts